Patents by Inventor Zeev Heimanson

Zeev Heimanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20230141118
    Abstract: Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of sickle cell disease (SCD).
    Type: Application
    Filed: April 13, 2021
    Publication date: May 11, 2023
    Inventors: Christopher Allen, Howard Franklin, Zeev Heimanson, Robert J. Israel, Thejasvi Ramakrishna
  • METHODS OF TREATING COVID-19 WITH RIFAXIMIN
    Publication number: 20230116647
    Abstract: Provided herein are methods for treating COVID-19 or associated GI symptoms with rifaximin compositions.
    Type: Application
    Filed: March 24, 2021
    Publication date: April 13, 2023
    Inventors: Maxime Barakat, Howard Franklin, Zeev Heimanson, Thejasvi Ramakrishna, Jason Lamar Vittitow
  • SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY
    Publication number: 20230111568
    Abstract: Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of Overt Hepatic Encephalopathy and complications associated with cirrhosis.
    Type: Application
    Filed: March 24, 2021
    Publication date: April 13, 2023
    Inventors: Zeev Heimanson, Robert J. Israel, Thejasvi Ramakrishna, Jason Lamar Vittitow
  • METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20220280478
    Abstract: Provided herein is the use of rifamycin SV the treatment of sickle cell disease (SCD).
    Type: Application
    Filed: March 4, 2022
    Publication date: September 8, 2022
    Applicant: Bausch Health Ireland, Limited
    Inventors: Ezra R. Lowe, Zeev Heimanson
  • USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS
    Publication number: 20220175764
    Abstract: The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.
    Type: Application
    Filed: November 18, 2021
    Publication date: June 9, 2022
    Applicant: Bausch Health Ireland Limited
    Inventors: Lorin K. Johnson, XiaoJun Nicole Deng, William J. Jo Siu, Robert J. Israel, Zeev Heimanson